Louisiana State Employees Retirement System Sells 300 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Louisiana State Employees Retirement System trimmed its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,800 shares of the specialty pharmaceutical company’s stock after selling 300 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Jazz Pharmaceuticals were worth $1,900,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JAZZ. Capital World Investors acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at $171,943,000. Swedbank AB bought a new position in shares of Jazz Pharmaceuticals during the second quarter valued at $106,936,000. Vestal Point Capital LP acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $89,175,000. Armistice Capital LLC grew its holdings in shares of Jazz Pharmaceuticals by 108.4% in the 4th quarter. Armistice Capital LLC now owns 651,626 shares of the specialty pharmaceutical company’s stock worth $80,150,000 after purchasing an additional 338,882 shares during the last quarter. Finally, Perpetual Ltd increased its position in shares of Jazz Pharmaceuticals by 54.0% during the 1st quarter. Perpetual Ltd now owns 475,018 shares of the specialty pharmaceutical company’s stock worth $57,202,000 after purchasing an additional 166,543 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Stock Down 0.6 %

NASDAQ:JAZZ opened at $113.87 on Friday. The stock has a 50-day simple moving average of $109.11 and a 200 day simple moving average of $113.14. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $146.70. The company has a market cap of $7.18 billion, a PE ratio of 23.48, a PEG ratio of 1.76 and a beta of 0.58. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.90 and a current ratio of 2.37.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of recent analyst reports. Needham & Company LLC reduced their price target on shares of Jazz Pharmaceuticals from $208.00 to $205.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Barclays lowered their price target on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Friday, May 3rd. HC Wainwright restated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Piper Sandler lowered their target price on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a report on Thursday, August 1st. Finally, UBS Group cut their price target on Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 2nd. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $173.07.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.